People taking TNF inhibitors, a kind of immunosuppressive drug used to treat rheumatoid arthritis and other autoimmune conditions, produced a weaker and shorter-lived antibody response after two doses of Pfizer’s COVID-19 vaccine, according to a new study. A third vaccine dose drove antibody levels back up, indicating that this additional dose may provide protection as the virus’s delta variant continues to spread.
